icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study
 
 
  Reported by Jules Levin
AASLD Annual Meeting 2017, Washington, DC, USA, October 20-24
 
Landis, CS; Sulkowski, MS; Reau, N; Lutchman, GA; Vainorius, M; Welzel, T; Zeuzem, S; Khalili, M; Nelson, DR; Lok, AS; Fried, MW; Dong, M; Terrault, N
 
Limited to treatment duration of 12 weeks for Per Protocol Population (N=306 ). * Overall Per protocol population (N=333 ) is defined as patients who completed or discontinued prematurely due to lack of efficacy and with available virological outcome.

1120171

1120172

1120173

1120174

1120175

1120176

1120177

1120178